HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.

Abstract
We describe the use of perfusion-permeability magnetic resonance imaging (ppMRI) to study hemodynamic parameters in human prostate tumor xenografts, following treatment with the vascular endothelial growth factor-A (VEGF) receptor tyrosine kinase inhibitor, ZD4190. Using a macromolecular contrast agent (P792), a fast MR imaging protocol and a compartmental data analysis, we were able to demonstrate a significant simultaneous reduction in tumor vascular permeability, tumor vascular volume and tumor blood flow (43%, 30% and 42%, respectively) following ZD4190 treatment (100 mg/kg orally, 24 h and 2 h prior to imaging). This study indicates that MR imaging can be used to measure multiple hemodynamic parameters in tumors, and that tumor vascular permeability, volume and flow, can change in response to acute treatment with a VEGF signaling inhibitor.
AuthorsC Pradel, N Siauve, G Bruneteau, O Clement, C de Bazelaire, F Frouin, S R Wedge, J L Tessier, P H Robert, G Frija, C A Cuenod
JournalMagnetic resonance imaging (Magn Reson Imaging) Vol. 21 Issue 8 Pg. 845-51 (Oct 2003) ISSN: 0730-725X [Print] Netherlands
PMID14599534 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Contrast Media
  • Quinazolines
  • Triazoles
  • Vascular Endothelial Growth Factor A
  • ZD 4190
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Capillary Permeability (drug effects)
  • Cell Line, Tumor
  • Contrast Media
  • Magnetic Resonance Angiography
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Neoplasms, Experimental (blood supply, drug therapy)
  • Neovascularization, Pathologic (pathology)
  • Quinazolines (therapeutic use)
  • Triazoles (therapeutic use)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: